Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Arava Adds Physical Function Claim, Bolded Liver Safety Warning

Executive Summary

Arava labeling has been updated to include more explicit liver function monitoring directions
Advertisement

Related Content

FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks
FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony
FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony
Aventis Arava hepatotoxicity
Aventis Arava Liver Toxicity Warning Is Satisfactory, FDA Arthritis Cmte. Says
Arthritis “Physical Function” Claim Can Be Shown In 6-12 Months, Cmte. Says
Remicade Physical Function Indication Is First Quality Of Life Claim For DMARDs
Serzone Liver Failure Relabeling Suggests Periodic Testing, Adds Black Box
PhRMA/FDA Hepatox Group Wants Research On Liver Monitoring
PhRMA/FDA Hepatox Group Wants Research On Liver Monitoring
Advertisement
UsernamePublicRestriction

Register

PS041988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel